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Abstract
The intestinal tract (i.e., the gut), is where the body’s nutrients are absorbed, and
is simultaneously inhabited by numerous microbes. An increasing body of
literature suggests a crucial role for the gut microbiome in modulating systemic
inflammatory disease. Psoriasis is a chronic systemic inflammatory disease and
its pathogenesis is related to the interaction between genetic susceptibility,
immune response and environmental triggers. The omics era has allowed
physicians to assess different aspects of psoriasis pathogenesis such as the
microbiome, infectome, and autoinfectome. Furthermore, diet appears to play an
important role in modulating disease activity, perhaps by influencing gut
microbes. Given these observations, we aimed to summarize the current
knowledge regarding skin-microbiome-gut-nutrients and psoriasis.
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Core tip: Psoriasis is a chronic systemic inflammatory disease and its pathogenesis is
related to the interaction between genetic susceptibility, immune response and
environmental triggers. The omics era has allowed physicians to study psoriasis
pathogenesis from different perspectives such as the microbiome, infectome, and
autoinfectome. Furthermore, diet appears to play an important role in modulating disease
activity. Given these observations, this review aimed to summarize the current
knowledge on skin-microbiome-gut-nutrients and psoriasis.
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INTRODUCTION
Psoriasis is alternatively regarded as an inflammatory[1], pruritic[2], autoimmune[3,4], or
even autoinflammatory[5] systemic chronic disease affecting not only the skin but the
whole  body,  providing  a  potential  explanation  for  the  numerous  comorbidities
discovered in relation to this disease[6-12]. The biomarker research performed in the
past decades identified substantial inadequacies in describing the wide spectrum of
psoriasis[13-15],  and failed to explain the complexity of psoriasis endotypes[16].  The
genetic background of psoriasis patients reveals that deficiency of the interleukin 1
(IL-1) receptor antagonist and deficiency of the IL-36 receptor antagonist are the only
recognized mutations[17],  conversely other psoriatic forms are considered complex
diseases, due to the intricate interaction between inherited susceptibility alleles and
environmental triggers[18]. In addition, epigenetic modifications seem to play a pivotal
role  in  developing  psoriasis,  establishing  environmental  triggers  as  potential
modulatory factors[19] as well as in response to anti-psoriatic therapies[20]. These new
findings provide a rationale for observed treatment loss-of-response and biologically
justify switching to alternative treatments in patient management[21-24]. Furthermore,
an increased body of  evidence suggests  a  crucial  role  for  the gut  microbiome in
modulating psoriasis;  linking the skin and gut microbiome[25].  The gut is  the site
where nutrients are absorbed and at the same time is inhabited by nutrient-modifying
microbes.  The  Skin-Microbiome-Gut-Nutrient  interaction  is  still  only  partially
understood; therefore, this review aimed to summarize the current knowledge in this
field.
PSORIASIS, DIET AND CIRCADIAN RHYTHM
Psoriasis is associated with metabolic and cardiovascular disease[6,26,27]. It has been
widely demonstrated that genetic and environmental factors including nutrition, may
strongly influence psoriatic pathogenesis and disease progression[28,29]. Increased body
mass and a high fat diet may trigger as well as exacerbate psoriasis[29]. Moderate to
severe psoriasis is frequently associated with numerous metabolic disorders including
obesity, diabetes, dyslipidemia, metabolic syndrome and non-alcoholic fatty liver
disease[30].  Fatty  acids  are  increased  in  obese  patients,  leading  to  augmented
inflammation and insulin  resistance.  Furthermore,  obesity  may also  affect  drug
pharmacokinetics and pharmacodynamics[29]. The option to treat psoriasis patients
with phototherapy is affected by body mass index; obese patients require an excessive
amount of photosensitizing drug which may lead to toxicities.  Obesity is also an
important risk factor for psoriasis, given that the relationship between obesity and
psoriasis is mutually interdependent[29]. Recent evidence has suggested an addition
role of vitamin D in the pathogenesis of several inflammatory skin diseases including
psoriasis[31]. An association between low levels of vitamin D and psoriasis has been
described[31]. Vitamin D also participates in keratinocyte proliferation and maturation.
Nevertheless, the potential value of vitamin D supplementation for psoriasis is still
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under debate[31]. Dietary antioxidants including omega 3 polyunsaturated fatty acids
derived from fish oil,  vitamin B12,  vitamin D and selenium have the capacity to
decrease oxidative stress and consequently lower reactive oxygen species production,
and this could be relevant in the pathogenesis of psoriasis. Based on these findings,
the Mediterranean diet has been proposed to slow disease progression[32,33].  All of
these endogenous factors contribute to the composition of the so-called “exposome”, a
measure of the whole complex of endogenous, ingested and not ingested, substances
that interact with the body that are capable of perturbing, modifying and modulating
vital functions[34]. Exposures capable of modulating psoriasis include tobacco, which
increases severity, flare frequency, and even the incidence of the psoriasis[35], alcohol[36]
and pollutants[37], even if the role of both alcohol and pollutants in psoriasis is still
debatable. Interestingly, the use of marijuana was recently related to secukinumab
resistance in a cohort of erythrodermic patients, focusing the attention on addiction
screening during intake medical history of psoriatic patients[38]. Anti-psoriatic drugs
are also capable of modulating taste, and consequently, the patient’s diet, as recently
described for both methotrexate[39] and apremilast[40].
Since the melatoninergic system was discovered in the epidermis, circadian rhythm
has been regarded as a possible modulator of inflammation[41], healing[42], aging[43],
neuroendocrine[44], and neoplastic conditions[45]. The cyclic nature of sunlight which
influences the suprachiasmatic nucleus (central clock) also influences other peripheral
tissue, including skin (peripheral clock), in different ways that are slowly beginning to
be understood by examining the mechanism(s) of their dysfunction[46,47]. The shift in
circadian rhythm may be occasional and transitory, as in the case of jet-lag during
intercontinental  flights[48],  or  in  the  case  of  the  Ramadan  fasting  months  for
Muslims[49,50], or more chronic, as in night shift workers[51,52]; however this effect is
particularly evident in psoriatic patients. Interestingly, night-shift workers exhibited
not only an increase in severity of psoriatic flares, but also an increased incidence of
psoriasis, suggesting that shifting the circadian rhythm (i.e., sleep and diet) may be a
risk factor for psoriasis[52]. Sunlight, in the form of narrow band UVB (NB-UVB), may
also be curative for psoriatic skin, allowing a reprograming of the circadian clock and
inhibition of autoimmune phenomena[53], however skin may also marginally adapt to
NB-UVB, an outcome termed photoadaptation[54].  Thus, sunlight is considered an
integral part of the exposome.
PSORIASIS, NUTRIENTS AND SKIN CANCER
The possible influence of nutrients on gene expression and clinical progression or
remission of psoriasis is not fully explored and may represent the main challenge in
approaching complementary therapy for psoriasis. It is reported that many dietetic
factors may exert beneficial effects, while others can aggravate inflammatory and
immune networks, thus leading to psoriasis comorbidities[55]. Previous studies have
reported the positive effects of low-energy diets, vegetarian diets, formula diet weight
loss programs, gluten-free or very low-calorie carbohydrate-free diet. It is believed
that  certain  vitamins  (e.g.,  A,  E  and  C),  and  oligo-elements  (e.g.,  iron,  copper,
manganese, zinc, and selenium) are anti-oxidants, leading to a reduction in oxidative
stress and decreased production of reactive oxygen species[55]. In fact, the disruption of
cell  redox  signaling  and involvement  of  oxidative  stress  in  the  pathogenesis  of
psoriasis was previously suggested, indicating that the potential therapeutic use of
dietary antioxidants in psoriasis may represent a novel complementary strategy[56].
Although limited data exist regarding the role of specific diet regimens in psoriasis,
the  main goal  for  clinicians  is  to  reduce  cardiac  risk  factors  and obesity-related
comorbidities.
Interestingly, psoriatic patients displayed a higher risk of cancer compared to the
general population; furthermore, this increase is not fully explained by anti-psoriatic
immunosuppressive  therapies,  so  several  real-life  or  ecological  studies  have
suggested an intimate relation with diet[57]. This theory is supported by the evidence
that  different  foods  modify  microRNA  expression  in  psoriatic  patients[28].  The
influence of a restrictive caloric diet was documented to be beneficial in relapsing
plaque  psoriasis,  and  may  also  decrease  the  risk  of  cancer [58-60].  Some  lipid
components, such as omega-3 polyunsaturated fatty acids may protect cells against
UV-induced DNA damage by increasing the expression of tumor-suppressor protein
p53, thus promoting cell cycle arrest and preventing melanoma development[61-63].
Solid cancers in psoriasis have been reported, especially those linked to alcohol and
smoking.  A higher risk of  non-melanoma skin cancers,  especially squamous cell
carcinoma  has  been  shown,  possibly  as  a  result  of  previous  exposure  to  8-
methoxypsoralen-ultraviolet-A (PUVA), cyclosporin, tumor necrosis factor-inhibitors
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and/or  methotrexate[64-66].  Consideration  of  malignancy  risk  associated  with
individual treatments and personal nutritional phenotype may help clinicians to make
optimal therapeutic decisions for individual patients.
MOUSE MODEL OF PSORIASIS AND DIET
The  "omics"  era  has  provided  researchers  with  new  powerful  techniques  (e.g.,
metagenomics) and has elucidated a myriad of dysregulated immune responses that
are heavily associated with the gut microbiota.  Previous research suggested that
ingested nutrients heavily affect the body’s microbial composition and community.
This has led to experimental approaches in mouse models of psoriasis. In recent years,
nutrition and microbial influence has been heavily implicated in psoriasis onset and
disease  severity.  The  contribution  of  nutrients  in  mouse  models  has  provided
valuable  insight  into  human  disease  regulation.  For  instance,  12-O-tetra-
decanoylphorbol-13-acetate (TPA), a known inflammatory signal transducer,  can
induce psoriasis-like skin lesions in mice, while lesions and proinflammatory cytokine
expression were significantly reduced in TPA-induced psoriasis by tangerine-derived
nutrient flavonoids: Nobiletin (Nob) and 5-hydroxy-6,7,8,3′,4′-pentamethoxyflavone
(5-HPMF)[67].  In  addition,  obesity,  a  result  of  poor  nutrition,  has  been shown to
exacerbate the severity of  psoriasiform dermatitis  in imiquimod-induced rodent
models[68]. Collectively, these results support the need to elucidate nutritional impact
on psoriasis severity. Research has suggested that monounsaturated fatty acid-rich
diets, such as the Mediterranean Diet have anti-inflammatory effects and slow the
progression  of  psoriasis  in  patients[33].  Poor  nutrition  has  been  associated  with
dysregulated metabolic functions and even more so, has been shown to be critical in
skin  disease  metabolic  homeostasis  compared  to  healthy  individuals.  Previous
research has shown evidence for biochemical skin barrier restoration through topical
administration of solenopsin, a compound of fire ant venom chemically similar to
ceramides,  and its  derivates  by  reducing inflammatory  markers  and improving
acanthosis in KC-Tie2 mice, an established rodent-model of psoriasis[69].
PSORIASIS AND THE MICROBIOME
Several lines of evidence confirmed the relationship between skin microorganisms
and psoriatic lesions, such as Group A β-hemolytic streptococcal infections  linked to
guttate psoriasis[70]. Other microorganisms including Staphylococcus aureus, Malassezia
and Candida albicans also appear to be involved in psoriasis pathogenesis[71]. The deep
inter-relationship between the mycobiome and microbiome seem to act as a disease-
modifier  in  psoriatic  patients.  Although  it  is  well  known that  the  gut  and  skin
microbiome deeply interact,  sparse information is  available  on the gut  and skin
mycobiome. Using high-throughput 16S rRNA gene sequencing, Alekseyenko et al[72],
found  that  psoriatic  plaques  had  an  abundance  of  the  following  bacteria:
Corynebacterium,  Propionibacterium,  Staphylococcus,  and Streptococcus.  Baker et al[73],
found that peptidoglycan, a cell wall component of Gram-positive bacteria including
Streptococci  and Staphylococci,  acts  as  a  T  cell  activator  in  psoriasis.  The  authors
observed that dermal papillae and cellular infiltrates of guttate and chronic plaque
skin lesions had higher numbers of peptidoglycan-containing cells compared to non-
lesional psoriatic skin. Psoriatic dermal Streptococcal- and Staphylococcal-specific CD4+
T  cell  lines  proliferated  and  produced  IFN-alfa  in  response  to  the  respective
peptidoglycan structures. Overall, these results suggest that peptidoglycans may be
responsible for T cell activation in psoriasis. Moreover, some studies have linked gut
microbiota and psoriasis.
Up to 10% of patients with inflammatory bowel disease (IBD) are diagnosed with
psoriasis[74]. Patients with psoriasis have a 3-fold higher risk of developing Crohn’s
disease as compared to the general population; and Crohn’s disease patients have a 7-
fold  higher  risk  of  developing  psoriasis[75].  Recently,  Scher  et  al[76],  using  pyro-
sequencing,  found  that  patients  with  psoriatic  arthritis  and  patients  with  skin
psoriasis had a decreased bacterial diversity and a reduced relative abundance of
some bacterial  taxa such as Akkermansia,  Ruminococcus,  and Pseudobutyrivibrio,  as
compared  to  healthy  controls.  Among  the  risk  factors  for  psoriatic  diseases
summarized in Table 1, overall, the alteration of gut microbiota may translate into
physiological consequences including poor regulation of intestinal immune responses
that may then affect distant organ systems[77-85]. Given the gut microbiome’s influence
on the Gut-Skin axis, probiotic supplementation may have a promising role in the
management of psoriatic patients. On this point, Gueniche et al[77], in a randomized
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double-blind placebo-controlled clinical study, showed that oral supplementation
with the probiotic strain Lactobacillus paracasei decreased skin sensitivity and increased
the rate of barrier function recovery.
INFECTOMICS AND AUTOINFECTOMICS IN PSORIASIS
The term “exposome” defines all environmental factors, including infectious and non-
infectious agents, to which a human is exposed over a lifetime[80]. The “microbiota” is
a  term used to describe the 10-100 trillion symbiotic  microbes harbored by each
human; the “microbiome” consists of the genes that these microbes harbor[81];  the
“infectome” is a part of the microbiome, referring to the collection of human exposure
to infectious agents; the “autoinfectome” describes a part of the microbiome that
includes the infectious agents  linked to the presence of  autoimmune diseases[82].
Figure  1  summarizes  the  main interactions  between the  exposome,  microbiome,
infectome and autoinfectome.  Recently a  systematic  review, which included 933
psoriatic arthritis patients and 1611 controls,  aimed to evaluate the link between
infections  (viral  and  bacterial  infections)  and  the  risk  of  psoriatic  arthritis  and
reported  a  controversial  result  that  exhibited  a  trend  but  failed  to  achieve
significance[83].  However,  differences  exist  between  infection,  colonization  and
dysbiosis, as suggested by several studies highlighting a different mycobiome and
microbiome  in  psoriasis,  psoriatic  arthritis  and  control  subjects[84].  In  fact,  a
dysregulation in  the  ratio  of  Firmicutes/Bacteroidetes  was  highlighted in  the  gut
microbiome of psoriatic patients; furthermore, Actinobacteria was reduced in the gut of
psoriatic patients. Gut dysbiosis was also found to be related to skin dysbiosis as
decreased beta-diversity in psoriatic skin microbiome is related to an increased risk of
developing psoriatic arthritis, and skin flora are now regarded as possible sensitive
and specific biomarkers to predict comorbidities in psoriatic patients[84].  The skin
microbiota in psoriasis patients seems to be less diverse when compared to healthy
persons with a decrease in Coprococcus  species[76],  and more recently Akkermansia
muciniphila[85]. The characteristic proinflammatory mediators of psoriatic skin lesions
have been reported to be the innate antimicrobial peptides and proteins (AMPs).
AMPs are a  diverse group of  small  molecules  (12–100 amino acid residues)  that
constitute  the  primary  effector  system  of  innate  immunity  against  microbes[86].
Although medical history certainly plays a crucial role in psoriasis management, it
has  some  limitations  such  as  recall  bias.  In  particular,  it  has  already  been
demonstrated that not all infections or even dysbiosis that are not clinically evident
are still capable of triggering an immune/autoimmune response. Currently, there is
limited,  evolving  information  suggesting  some  benefit  from  fecal  microbiota
transplantation, although durability of response is a concern and currently under
investigation[87,88].
TREATMENT OF PSORIASIS: TAKING INTO ACCOUNT
INTERACTIONS WITH DIET AND MICROBIOME
Drug therapies are an important consideration for alteration of the cutaneous and gut
microbiome[78,89] as well as the mycobiome; however, few studies have explored this
topic, and are summarized in Table 2.
To date IL-17/IL-17RA signaling has been demonstrated to be a key component in
regulating Candida in the gut microbiome[79]. Furthermore, psoriatic arthritis and IBD
have genetic and environmental similarities, highlighting that microbiome dysbiosis
may affect autoimmune diseases[78]. T-cell activation is an important mechanism of
psoriasis, and dysbiosis has been associated with the differentiation of T-cells into
effector T cells with fewer regulatory T-cells resulting in changes in the levels of
cytokines. In particular, Th17 inhibitors produced the best response compared to
patients treated with tumor necrosis factor-α and IL-23 inhibitors[78]. It is interesting to
note that this Th-17 mediated response may not translate to the skin, as the skin
microbiome  could  prevent  the  development  of  psoriatic  plaques  in  these
individuals[3,79]. It is possible that transplanting fecal microbiota could improve or
resolve the dysbiosis present in psoriatic arthritis[79]. Fecal microbiota transplants have
been used with success in IBD. In fact, Kragsnaes et al[90] are currently exploring fecal
microbiota transplantation (FMT) in patients with psoriatic arthritis currently on
methotrexate to examine their treatment response. Evaluating evidence of the efficacy
of FMT is likely due to be complicated by various factors including antibiotic use,
prior psoriasis therapy, subtype of psoriasis and comorbidities which similarly affect
the  gut  or  skin  microbiome[91].  Future  studies  are  needed  to  identify  potential
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Table 1  Synthesis of psoriasis risk factors reporting reference number, first author surname, year of publication, population risk factors
reported in each study and the type of psoriasis
Ref. Year Studied population Psoriasis risk factors Type of psoriasis
Barrea et al[29] 2016 Human Obesity Not specified
Kanemaru et al[68] 2015 Animal - Mice Obesity Psoriasiform dermatitis
Dauden et al[30] 2018 Human Metabolic disorders Not specified
Barrea et al[31] 2017 Human Reduction vitamin D Not specified
Lin et al[56] 2016 Human Oxidative stress Not specified
Yang et al[67] 2018 Animal - Mice 12-O-tetradecanoylphorbol-
13-acetate administration
Psoriasis-like skin lesions
Ottman et al[70] 2012 Human Beta-hemolytic streptococcal
infections
Guttate psoriasis
Zeng et al[71] 2017 Human Staphylococcus aureus,
Malassezia and Candida
albicans infections
Not specified
Alekseyenko et al[72] 2013 Human Corynebacterium,
Propionibacterium,
Staphylococcus, and
Streptococcus infections
Psoriatic plaques
Baker et al[73] 2006 Human Higher numbers of
peptidoglycan-containing
cells
Guttate and chronic plaques
Oliveira Mde et al[75] 2015 Human Inflammatory bowel disease
(i.e., Crohn’s disease)
Not specified
Scher et al[76] 2015 Human Significant reduction in
Akkermansia, Ruminococcus,
and Pseudobutyrivibrio in gut
microbiota
Psoriasic arthritis
Tan et al[85] 2018 Human Reduction of Coprococcus
species and Akkermansia
muciniphila in gut microbiota
Psoriatic arthritis
modulators of the gut and skin microbiome, and identify which medications would be
optimal for a patient’s individual microbiome signature.
CONCLUSION
The  interaction  of  Microbiome-Gut-Nutrients  in  psoriasis  is  beginning  to  be
understood with  the  advent  of  improved omics  technologies  and their  possible
integration with each other in order to more precisely separate psoriasis  patient
endotypes. The transition from immune-targeted therapy to precision-based therapy
will be based on the mix between biological signature, the endotype, and potential
specific interaction within the exposome.
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Table 2  Synthesis of psoriasis proposed treatments including reporting reference number, first author surname, year of publication,
population risk factors reported in each study and the type of psoriasis
Ref. Year Study type Studied population Proposed treatment Type of psoriasis
Barrea et al[32], Phan et
al[33]
2015, 2018 Cohort Human Dietary antioxidants
(omega 3 polyunsatured
fatty acids derived from
fish oil, vitamin B12,
vitamin D and
selenium)
Not specified
Subbiah et al[55] 2010 Review - Low-energy diets,
vegetarian diets,
formula diet weight loss
programs, gluten-free or
very low-calorie
carbohydrate-free diet
Not specified
Subbiah et al[55], Lin et
al[85]
2010, 2016 Review - Dietary antioxidants:
Vitamins (A, E and C),
and oligo-elements
(iron, copper,
manganese, zinc, and
selenium)
Not specified
Murzaku et al[61], Upala
et al[62], Morken et al[63]
2014, 2017, 2011 Review, systematic
review, pilot study
Human Omega-3
polyunsaturated fatty
acids
Not specified
Yang et al[67] 2018 RCT Animal – mice Nobiletin (Nob) and 5-
hydroxy-6,7,8,3′,4′-
pentamethoxyflavone
(5-HPMF)
Not specified
Arbiser et al[69] 2017 RCT Animal - mice Topical administration
of solenopsin analogs
Not specified
Gueniche et al[77] 2014 RCT Human Oral supplementation
with the probiotic
Lactobacillus paracasei
Not specified
Eppinga et al[78] 2014 Review - Th17, TNF-α and IL-22
inhibitors
Psoriatic arthritis
Castelino et al[79] 2014 Review - Transplant of fecal
microbiome
Psoriatic arthritis
RCT: Randomized controlled trial; TNF: Tumor necrosis factor; IL: Interleukin 1.
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Figure 1
Figure 1  The figure describes the complex panorama of the exposome. The exposome represent all environmental exposures, from infectious and noninfectious
causes. Environmental exposure changes the internal chemical environment that can lead to alterations in the microbiome. The microbiome is the number of all genes
of symbiotic microbes harbored by each human. The fraction of the microbiome concerning the collection of human exposure to infectious agents is represented by
the infectome. The autoinfectome is the part of the infectome that contains the infectious agents causing autoimmune diseases.
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